FIELD: chemistry.
SUBSTANCE: invention relates to the derivative of 1'-bromo-2',3',4'-trimethoxybenzo[5',6':4,5]-(aR, 1S)-1-acetamido-6,7-dihydrocyclohepta[3,4-ƒ]-1H-indole and its use as the active component of oncology drugs for the cancer treatment. The derivative of 1'-bromo-2',3',4'-trimethoxybenzo [5',6':4.5]-(aR, 1S)-1-acetamido-6.7-dihydrocyclohepta[3.4-ƒ)-1H-indole is represented by the general formula , in which X is the substituent, X=H, Me; R is the substituent, R=Ph, CH2OH, CH (CH3) OH, CH2CH2OH, CH2OAc.
EFFECT: compounds have the high apoptosis-inducing activity and activity in inhibiting the proliferation of the tumour cells.
8 cl, 2 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVE OF 1",2",3"-TRIMETHOXIBENZO[5",6":5',4']1H-(aR,1S)-1-ACETAMIDO-6',7'-DIHYDROCYCLOHEPTA[2',3'-f]-2,3-DIHYDROFURAN AND ITS APPLICATION | 2018 |
|
RU2678440C1 |
1',2',3'-TRIMETHOXYBENZO[4',5':4,5]-6,7-DIHYDROCYCLOHEPTA-[3,2-f]-1H-1-METHYL INDOLE DERIVATIVE AND USE THEREOF | 2012 |
|
RU2500671C1 |
1',2',3'-TRIMETHOXYBENZO[4',5':4,5]-6,7-DIHYDROCYCLOHEPTA-[2,3-e]-1H-1-METHYL INDOLE DERIVATIVE AND USE THEREOF | 2012 |
|
RU2500670C1 |
1',2',3'-TRIMETOXIBENZO[5',6:5,4]-1H-6,7-DIHYDROCYCLOGEPTA[3,2-f]BENZOFURAN DERIVATIVE AND ITS APPLICATION | 2015 |
|
RU2593998C1 |
DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
DISPIROINDOLINONES BASED ON RHODANINES AS P53-MDM2 INHIBITORS OF PROTEIN-PROTEIN INTERACTION | 2019 |
|
RU2730286C1 |
MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | 2011 |
|
RU2576036C2 |
GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENT | 2008 |
|
RU2450001C2 |
HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | 2019 |
|
RU2812128C2 |
SULFONAMIDE PERI-SUBSTITUTED BICYCLES FOR TREATMENT OF OCCLUSIVE AFFECTION OF ARTERIES | 2005 |
|
RU2403240C2 |
Authors
Dates
2017-09-08—Published
2016-11-30—Filed